JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.
about
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasmsMolecular diagnostics of myeloproliferative neoplasms.Myeloproliferative neoplasm stem cells.Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer developmentPrevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation.Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis.The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari Syndrome without myeloproliferative neoplasm.Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia.V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kineticsQuantitative competitive allele-specific TaqMan duplex PCR (qCAST-Duplex PCR) assay: a refined method for highly sensitive and specific detection of V617F mutant allele burdens
P2860
Q28392728-12E5B684-B8A0-47A3-BC56-9B2BEB2FA2A9Q38464571-D8021BD8-0BC5-4A99-A89E-953279978F43Q39118859-079A3500-39EA-4E13-8218-806E112B7D1BQ41576528-0295593D-95C7-4A22-B279-78DD161B7790Q46886345-ECF9C25D-CF0E-44A4-B4B0-01A60C1F973AQ48285438-98DC35A6-7FF7-48E6-8AAE-6C224E29D76CQ48368306-0677FB28-DF0A-4E7C-8D70-1E7B0E6126B8Q49324407-4576183A-2BA3-431F-94CF-1A75E3825729Q49834761-7C8B7E15-9B5C-4510-9275-EBE1B2B8E23FQ53680800-AAAAB302-F820-4359-9F8D-A025098A419CQ54241568-97002E17-00CB-4374-980E-B6BAF730DDFCQ55015961-83AB8BA4-B15D-4B2B-B588-0D7328C89BE5Q55249687-1F390CAF-CCAC-48D3-B519-5A4833D70663Q57743533-E1A81FF1-F2A4-40D8-BEB5-9BED3AE3422BQ58793774-FFE6EF30-74C3-49CB-AC45-23F2B18914E9
P2860
JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
JAK2V617F somatic mutation in ...... elopment and progression rate.
@ast
JAK2V617F somatic mutation in ...... elopment and progression rate.
@en
type
label
JAK2V617F somatic mutation in ...... elopment and progression rate.
@ast
JAK2V617F somatic mutation in ...... elopment and progression rate.
@en
prefLabel
JAK2V617F somatic mutation in ...... elopment and progression rate.
@ast
JAK2V617F somatic mutation in ...... elopment and progression rate.
@en
P2860
P50
P1433
P1476
JAK2V617F somatic mutation in ...... elopment and progression rate.
@en
P2093
Camilla Nielsen
Henrik S Birgens
P2860
P304
P356
10.3324/HAEMATOL.2014.107631
P577
2014-06-06T00:00:00Z